Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

ClinicalTrials.gov ID: NCT02436759

Public ClinicalTrials.gov record NCT02436759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.

Study identification

NCT ID
NCT02436759
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Enrollment
140 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2015 (Type not available)
Primary completion
Nov 2016 (Actual)
Completion
Nov 2016 (Actual)
Last update posted
Oct 28, 2021

2015 – 2016

United States locations

U.S. sites
14
U.S. states
7
U.S. cities
14
Facility City State ZIP Site status
Not listed Artesia California 90701 —
Not listed Newport Beach California 92663 —
Not listed Rancho Cordova California 95670 —
Not listed Santa Maria California 93454 —
Not listed Fort Myers Florida 33901 —
Not listed Largo Florida 33773 —
Not listed Plantation Florida 33324 —
Not listed Sarasota Florida 34239 —
Not listed Roswell Georgia 30076 —
Not listed Pittsburg Kansas 66762 —
Not listed Shawnee Mission Kansas 66204 —
Not listed Mason Ohio 45040 —
Not listed Kingston Pennsylvania 18704 —
Not listed Nashville Tennessee 37215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02436759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2021 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02436759 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →